The introduction of captopril, the first drug to inhibit selectively the angiotensin converting enzyme, marked an important development in the treatment of hypertension and refractory cardiac failure. 2 Unfortunately, its usefulness has been decreased by the development of numerous side effects, which commonly occur during treatment. These include renal impairment, neutropenia, agranulocytosis, hyperkalaemia, proteinuria, loss of taste and hypotension.3 One of the commonest side effects is an erythematous maculopapular skin rash, which occurs in up to 30% of patients treated with the drug4 and which seems to be related to dose; symptoms may disappear with continued treatment at a lower dose. Enalapril, a newer drug with a similar action but a different chemical structure, has been claimed to be free from these problems,5 though a single case report contests this. 6 We reported a distinct more severe cutaneous reaction to captopril.' Patients developed an urticated scaling erythematous rash, with some eczematous features. Considerable clinical oedema occurred, with some infiltration, particularly of more acute lesions. There was little clinical resemblance to any of the forms of cutaneous T cell lymphoma (CTCL) . More chronic lesions became lichenified and hyperkeratotic on a background of erythroderma. The rash usually started on the hands and face and proceeded to generalised spread if treatment was not stopped (Fig. 1) . Resolution was slow even after the drug was discontinued.
This rash seems to be allergic in nature as it is not Accepted for publication 25 March 1986 dose related. The rash will not resolve unless the drug is stopped completely and it will recur rapidly on rechallenge. The histological features of all biopsy specimens examined to date have been similar; the pattern seen is not typical of a drug eruption. Indistinguishable clinical and histological features have been observed after treatment with nalapril.
Material and methods
Eight biopsy specimens from seven patients were identified retrospectively (Table 1) . Paraffin sections (5pm) stained with haematoxylin and eosin were reviewed, but no further procedures were undertaken. Two cases were identified prospectively (Table 1) . Skin biopsy specimens from these patients were sent unfixed to the laboratory, divided, and treated as follows:
1 Tissue was fixed in formalin, processed, and embedded routinely in paraffin. Sections (Fig. 2) . In seven biopsy specimens many of the lymphocytes had large nuclei up to 10 pm across with cerebriform nuclear contours and dense chromatin. The cytoplasm was scanty and the cell membranes indistinct. (Fig. 3) . In every biopsy specimen but one (case 2) mononuclear cells were also seen infiltrating the epidermis; in several cases these were recognisable as the atypical lymphoid cells described above (Fig. 4) . Numerous mitoses were seen in the dermal infiltrate and occasionally in the epidermis. Focal spongiosis was noted in every case but one(case 3), usually in areas with atypical lymphocytes in the epidermis. Other features present in the specimens in varying degree included irregular acanthosis (six of 10), hyperkeratosis (eight of 10), and focal areas of parakeratosis (nine of 10), which were not related to areas of spongiosis or infiltration (Fig. 2) . None of these features is specific, but the appearances are not those commonly seen in drug eruptions. They closely resemble the early stages of cutaneous T cell lymphoma (CTCL); indeed, in case 1 an experienced pathologist had suggested that the diagnosis of mycosis fungoides should be considered, despite being aware of the patient's drug history. Table 2 illustrates the results of the immunocytochemical studies. They indicate that the lymphoid cells in dermis and epidermis were T lymphocytes (Fig. 5) The presence of macrophages and cells with convoluted nuclei (T lymphocytes) around small dermal blood vessels was confirmed. Lymphocytes could not be shown in the epidermis in the small amount of material available.
Discussion
Recognition of this complication of treatment with captopril and enalapril is important for both clinician and histopathologist. Skin rashes are a well recognised complication of treatment with captopril, but they are usually trivial and will usually resolve after a reduction in dosage,2 or even if the original dose is maintained.7 The rash described here is more serious; it will not resolve unless the drug is stopped. If treatment continues it may progress to erythrodermia, which may be life threatening.
It has been claimed that enalapril does not cause the dose dependent rash seen with captopril,5 but we found that this dose independent eruption can develop during treatment with either drug. It thus follows that a patient who develops a rash during treatment with enalapril is likely to be suffering from the more serious dose independent eruption. A reduction in dosage will therefore be inadequate, and treatment must be stopped completely.
There are histological similarities between the drug induced rash described here and the early manifestations of CTCL, which may provide difficulties for the histopathologist. Large, atypical, cerebriform lymphoid cells, which are cytologically indistinguishable from mycosis cells8 are easily found in captopril rashes. Another similarity with CTCL is the epidermotropism exhibited by the lymphocytic infiltrate. In both conditions the epidermotropic lymphocytes are associated with foci of epidermal spongiosis; Pautrier abeesses, however, have not been seen in the captopril rashes.
In contrast to typical CTCL, the mononuclear cell infiltrate associated with these skin rashes is not band .0
Severe cutaneous reactions to captopril and enalapril like but shows a perivascular orientation. 
